Invivyd, Inc. Files 8-K
Ticker: IVVD · Form: 8-K · Filed: Jan 27, 2025 · CIK: 1832038
| Field | Detail |
|---|---|
| Company | Invivyd, INC. (IVVD) |
| Form Type | 8-K |
| Filed Date | Jan 27, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, filing, corporate-update
Related Tickers: IVVD
TL;DR
Invivyd (IVVD) filed an 8-K, check for updates.
AI Summary
Invivyd, Inc. filed an 8-K on January 27, 2025, to report other events and financial statements. The company, formerly known as Adagio Therapeutics, Inc., is incorporated in Delaware and headquartered in Waltham, MA. This filing does not contain specific financial figures or event details beyond its classification.
Why It Matters
This 8-K filing indicates that Invivyd, Inc. has submitted a current report to the SEC, which may contain material updates for investors.
Risk Assessment
Risk Level: low — The filing is a routine 8-K without specific negative or positive financial disclosures, making the immediate risk low.
Key Players & Entities
- Invivyd, Inc. (company) — Registrant
- Adagio Therapeutics, Inc. (company) — Former Name
- January 27, 2025 (date) — Report Date
- Waltham, MA (location) — Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing for Invivyd, Inc.?
The primary purpose of this 8-K filing is to report 'Other Events' and 'Financial Statements and Exhibits' as of January 27, 2025.
When was Invivyd, Inc. formerly known as?
Invivyd, Inc. was formerly known as Adagio Therapeutics, Inc., with a date of name change on November 12, 2020.
Where are Invivyd, Inc.'s principal executive offices located?
Invivyd, Inc.'s principal executive offices are located at 1601 Trapelo Road, Suite 178, Waltham, MA 02451.
What is Invivyd, Inc.'s IRS Employer Identification Number?
Invivyd, Inc.'s IRS Employer Identification Number is 851403134.
What is the SIC code for Invivyd, Inc.?
The Standard Industrial Classification (SIC) code for Invivyd, Inc. is 2836, which corresponds to BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES).
Filing Stats: 453 words · 2 min read · ~2 pages · Grade level 10.8 · Accepted 2025-01-27 07:07:11
Key Financial Figures
- $0.0001 — ch registered Common stock, par value $0.0001 per share IVVD The Nasdaq Stock Mar
Filing Documents
- ivvd-20250127.htm (8-K) — 54KB
- ivvd-ex99_1.htm (EX-99.1) — 35KB
- img59752938_0.jpg (GRAPHIC) — 84KB
- 0000950170-25-008995.txt ( ) — 331KB
- ivvd-20250127.xsd (EX-101.SCH) — 27KB
- ivvd-20250127_htm.xml (XML) — 5KB
01
Item 8.01. Other Events. On January 27, 2025, Invivyd, Inc. issued a press release entitled "Invivyd Provides Another Positive SARS-CoV-2 Variant Data Analysis to Satisfy U.S. FDA's Gating Request for Completing Its Review of EUA Request for PEMGARDA (pemivibart) for the Treatment of Mild-to-Moderate COVID-19 in Certain Immunocompromised Patients." A copy of the press release is filed herewith as Exhibit 99.1 and is incorporated by reference in this Item 8.01.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release, dated January 27, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. INVIVYD, INC. Date: January 27, 2025 By: /s/ Jill Andersen Jill Andersen Chief Legal Officer and Corporate Secretary